Lexicon Pharmaceuticals LXRX Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's investment proceeds?
- Lexicon Pharmaceuticals (LXRX) reported investment proceeds of $35.7M in Q1 2026.
- How has Lexicon Pharmaceuticals's investment proceeds changed year-over-year?
- Lexicon Pharmaceuticals's investment proceeds decreased by 66.2% year-over-year, from $105.55M to $35.7M.
- What is the long-term trend for Lexicon Pharmaceuticals's investment proceeds?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's investment proceeds has grown at a 61.0% compound annual growth rate (CAGR), from $37.59M to $252.86M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.